See more : Second Sight Medical Products, Inc. (EYES) Income Statement Analysis – Financial Results
Complete financial analysis of SELLAS Life Sciences Group, Inc. (SLS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SELLAS Life Sciences Group, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- BNP Paribas SA (BNPQY) Income Statement Analysis – Financial Results
- Hanpin Electron Co., Ltd. (2488.TW) Income Statement Analysis – Financial Results
- OUTLOOKCONSULTING CO LTD (5596.T) Income Statement Analysis – Financial Results
- Palco Metals Limited (PALCO.BO) Income Statement Analysis – Financial Results
- Multi-Chem Limited (AWZ.SI) Income Statement Analysis – Financial Results
SELLAS Life Sciences Group, Inc. (SLS)
About SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.00M | 7.60M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 9.32M | 2.49M | 2.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 100.00K | 200.00K | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 355.00K | 1.40M | 520.00K | 0.00 | 20.79M | 0.00 | 0.00 | 0.00 | 11.41M | 0.00 |
| Gross Profit | 0.00 | 900.00K | 7.40M | 1.90M | 0.00 | 0.00 | 0.00 | -3.00K | -355.00K | 7.92M | 1.97M | 2.04M | -20.79M | 0.00 | 0.00 | 0.00 | -11.41M | 0.00 |
| Gross Profit Ratio | 0.00% | 90.00% | 97.37% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 84.94% | 79.09% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.01M | 30.27M | 21.37M | 9.28M | 7.29M | 18.32M | 6.07M | 19.86M | 23.61M | 28.35M | 21.08M | 14.61M | 11.54M | 7.87M | 8.89M | 7.05M | 6.75M | 1.30M |
| General & Administrative | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 6.86M | 8.75M | 8.63M | 4.87M | 3.74M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.39M | 0.00 | 0.00 | 2.63M | 931.00K | 0.00 |
| SG&A | 13.86M | 12.58M | 11.32M | 9.60M | 9.92M | 12.77M | 15.09M | 12.01M | 10.61M | 31.34M | 14.60M | 6.59M | 9.25M | 8.75M | 8.63M | 7.50M | 4.67M | 633.00K |
| Other Expenses | 0.00 | 10.00M | 5.70M | 0.00 | 0.00 | -3.03M | 0.00 | 0.00 | 509.00K | 170.00K | 37.00K | -13.18M | 9.25M | 0.00 | 0.00 | 7.50M | 0.00 | 0.00 |
| Operating Expenses | 37.87M | 42.85M | 32.69M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 60.14M | 35.81M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Cost & Expenses | 37.87M | 42.95M | 32.89M | 18.88M | 17.21M | 31.09M | 21.16M | 31.87M | 34.22M | 61.54M | 36.33M | 21.20M | 20.79M | 16.63M | 17.52M | 14.55M | 11.41M | 2.41M |
| Interest Income | 525.00K | 317.00K | 6.00K | 26.00K | 118.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.00K | 448.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 118.00K | 266.00K | 462.00K | 3.51M | 760.00K | 1.11M | 807.00K | 33.00K | 0.00 | 5.00K | -5.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 37.87M | 457.00K | 1.27M | 377.00K | 17.21M | 22.04M | 3.00K | 3.00K | 355.00K | 440.00K | 452.00K | 49.00K | 163.00K | 172.00K | 162.00K | 131.00K | 36.00K | 0.00 |
| EBITDA | 529.00K | -31.95M | -19.66M | -16.40M | 668.00K | 0.00 | -23.04M | -15.99M | -37.48M | -36.61M | 7.63M | -34.38M | -11.32M | -11.82M | -18.22M | -14.24M | -10.93M | -2.41M |
| EBITDA Ratio | 0.00% | -4,228.20% | -390.08% | -888.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -733.32% | 306.71% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -37.87M | -41.95M | -25.29M | -16.98M | -20.04M | -31.09M | -23.04M | -31.87M | -34.22M | -52.22M | -33.84M | -21.20M | -20.79M | -16.63M | -17.52M | -14.55M | -11.41M | -2.41M |
| Operating Income Ratio | 0.00% | -4,195.00% | -332.82% | -893.79% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -560.38% | -1,360.68% | -1,040.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 529.00K | 649.00K | 4.36M | 208.00K | 668.00K | 2.54M | -7.79M | 5.13M | -4.37M | 13.62M | -41.79M | -13.18M | 9.30M | 4.63M | -867.00K | 180.00K | 448.00K | 0.00 |
| Income Before Tax | -37.34M | -41.30M | -20.94M | -16.77M | -19.37M | -29.05M | -23.50M | -10.86M | -38.59M | -36.61M | -75.63M | -34.38M | -11.49M | -11.99M | -18.39M | -14.37M | -10.97M | -2.41M |
| Income Before Tax Ratio | 0.00% | -4,130.10% | -275.47% | -882.84% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,040.85% | -1,686.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -649.00K | -237.00K | -17.00K | -81.00K | -1.38M | 253.00K | 243.00K | 365.00K | -15.45M | 1.05M | -1.05M | -9.30M | -4.63M | 867.00K | 0.00 | 25.00K | 0.00 |
| Net Income | -37.34M | -40.65M | -20.70M | -16.76M | -19.29M | -27.67M | -23.75M | -23.55M | -63.90M | -36.61M | -76.68M | -34.97M | -11.49M | -11.99M | -18.39M | -14.37M | -10.99M | -2.41M |
| Net Income Ratio | 0.00% | -4,065.20% | -272.36% | -881.95% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -392.81% | -3,083.15% | -1,715.85% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| EPS Diluted | -1.34 | -2.10 | -1.34 | -2.10 | -7.54 | -105.80 | -507.49 | -3.55K | -12.35K | -9.20K | -25.51K | -16.80K | -9.48K | -19.60K | -34.05K | -31.38K | -26.04K | -5.73K |
| Weighted Avg Shares Out | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.17K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
| Weighted Avg Shares Out (Dil) | 27.78M | 19.40M | 15.48M | 7.98M | 2.56M | 261.54K | 46.81K | 6.64K | 5.18K | 3.98K | 3.01K | 2.08K | 1.21K | 612.00 | 540.00 | 458.00 | 422.00 | 420.00 |
SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Acute Myeloid Leukemia
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). “We are excited to...
SELLAS Announces Positive Topline Data in Lymphoma Cohort from SLS009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met
- 52 Relapsed and Refractory Lymphoma Patients Enrolled: 96% Alive at Last Assessment Indicating Favorable Survival Benefit -
SELLAS Life Sciences to Participate in the Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue Without any Modifications
REGAL Interim Analysis Expected by Late 2023/Early 2024 Enrollment Expected to be Completed in Q4 2023 NEW YORK, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company...
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2023 Financial Results
First Patients Dosed in Phase 2a Clinical Trial of SLS009 (formerly GFH009) in Acute Myeloid Leukemia with Topline Data Expected in 4Q 2023
SELLAS to Participate in Maxim Group Healthcare Virtual Conference
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
SELLAS Life Sciences to Present Phase 3 REGAL Trial in Progress Poster at 2023 ASCO Annual Meeting
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced...
3D Systems Expands Portfolio of Selective Laser Sintering
Affordable, turnkey, closed-loop solutions make Selective Laser Sintering (SLS) accessible for smaller manufacturing environments More than 20 materials to address range of applications for industrial, medical devices & equipment, academic markets Sets new standards for customer ease of installation, ease...
Sellas Life Sciences raises $20 million from public offering of stock, warrants
Sellas Life Sciences Group Inc. SLS, -3.40% said Friday that it raised $20.0 million, through the public sale of common shares and warrants to buy stock. Shares of the biopharmaceutical company, which is focused on cancer treatments, plummeted 43.1% in...
Source: https://incomestatements.info
Category: Stock Reports